Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness

Prostate

Volumn 72, Issue 9, 2012, Pages 966-976

  Terada, Naoki ^a   Shiraishi, Takumi ^a   Zeng, Yu ^a   Mooney, Steven M ^a   Yeater, David B ^a   Mangold, Leslie A ^a   Partin, Alan W ^a   Kulkarni, Prakash ^a   Getzenberg, Robert H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cAMP dependent protein kinase; Cyr61; prostate cancer; serum marker

Indexed keywords

ANDROGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYSTEINE RICH PROTEIN 61; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGGRESSIVENESS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CELL INVASION; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; CORRELATIONAL STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPERNATANT; UPREGULATION;

AGED; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYSTEINE-RICH PROTEIN 61; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861101983     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21501     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Parekh DJ, Ankerst DP, Troyer D, Srivastava S, Thompson IM,. Biomarkers for prostate cancer detection. J Urol 2007; 178 (6): 2252-2259.
3. Lau LF, Nathans D,. Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J 1985; 4 (12): 3145-3151.
4. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF,. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans. Endocrinology 2002; 143 (4): 1441-1450.
5. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF,. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998; 95 (11): 6355-6360.
6. Menendez JA, Mehmi I, Griggs DW, Lupu R,. The angiogenic factor CYR61 in breast cancer: Molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003; 10 (2): 141-152.
7. Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH, Chen WJ, Kuo ML,. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/ cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005; 11 (16): 5809-5820.
8. Chien W, Kumagai T, Miller CW, Desmond JC, Frank JM, Said JW, Koeffler HP,. Cyr61 suppresses growth of human endometrial cancer cells. J Biol Chem 2004; 279 (51): 53087-53096.
9. Bleau AM, Planque N, Perbal B,. CCN proteins and cancer: Two to tango. Front Biosci 2005; 10: 998-1009.
10. Feng P, Wang B, Ren EC,. Cyr61/CCN1 is a tumor suppressor in human hepatocellular carcinoma and involved in DNA damage response. Int J Biochem Cell Biol 2008; 40 (1): 98-109.
11. Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr, Brekken RA, Fleming JB,. Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. J Am Coll Surg 2005; 200 (3): 371-377.
12. Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wirth MP,. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998; 36 (2): 85-91.
13. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, Kakehi Y, Getzenberg RH,. Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays. Proc Natl Acad Sci USA 2002; 99 (11): 7598-7603.
14. Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, Xie D,. Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer 2008; 99 (10): 1656-1667.
15. D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH,. Extracellular matrix associated protein CYR61 is linked to prostate cancer development. J Urol 2010; 183 (4): 1604-1610.
16. D'Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH,. Decreased expression of cyr61 is associated with prostate cancer recurrence after surgical treatment. Clin Cancer Res 2010; 16 (23): 5908-5913.
17. Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, Hatanaka T, Getzenberg RH, Kakehi Y,. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology 2004; 145 (6): 2929-2940.
18. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J,. LPA receptors: Subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186.
19. Merkle D, Hoffmann R,. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell Signal 2011; 23 (3): 507-515.
20. Cox ME, Deeble PD, Lakhani S, Parsons SJ,. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999; 59 (15): 3821-3830.
21. Inoue T, Leman ES, Yeater DB, Getzenberg RH,. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Prostate 2008; 68 (10): 1048-1056.
22. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H,. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170 (5): 1872-1876.
23. Chen CC, Lau LF,. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009; 41 (4): 771-783.
24. Mills GB, Moolenaar WH,. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3 (8): 582-591.
25. Kulkarni P, Getzenberg RH,. High-fat diet, obesity and prostate disease: The ATX-LPA axis? Nat Clin Pract Urol 2009; 6 (3): 128-131.
26. Chuan YC, Pang ST, Cedazo-Minguez A, Norstedt G, Pousette A, Flores-Morales A,. Androgen induction of prostate cancer cell invasion is mediated by ezrin. J Biol Chem 2006; 281 (40): 29938-29948.
27. Sakamoto S, Yokoyama M, Prakash K, Tsuruha J, Masamoto S, Getzenberg RH, Kakehi Y,. Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia. J Biomol Screen 2003; 8 (6): 701-711.
28. Sarker D, Reid AH, Yap TA, de Bono JS,. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15 (15): 4799-4805.
29. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD,. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58 (6): 843-848.
30. Kandirali E, Boran C, Serin E, Semercioz A, Metin A,. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology 2007; 70 (4): 743-747.
31. Sakamoto S, Yokoyama M, Aoki M, Suzuki K, Kakehi Y, Saito Y,. Induction and function of CYR61 (CCN1) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation. Prostate 2004; 61 (4): 305-317.
32. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB,. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009; 15 (6): 539-550.
33. Dorsam RT, Gutkind JS,. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7 (2): 79-94.
34. Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O,. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 2010; 70 (4): 1606-1615.
35. Marinissen MJ, Gutkind JS,. G-protein-coupled receptors and signaling networks: Emerging paradigms. Trends Pharmacol Sci 2001; 22 (7): 368-376.
36. Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, Wu XX,. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: Relevance to prostate cancer and benign hyperplasia. Prostate 2009; 69 (3): 283-292.
37. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25 (2): 276-308.
38. Epstein JI, Pizov G, Walsh PC,. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71 (11): 3582-3593.
39. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT,. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167 (2 Pt 1): 528-534.
40. Karan D, Thrasher JB, Lubaroff D,. Prostate cancer: Genes, environment, immunity and the use of immunotherapy. Prostate Cancer Prostatic Dis 2008; 11 (3): 230-236.
41. Chen Y, Du XY,. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 2007; 100 (6): 1337-1345.
42. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, Casey PJ, Daaka Y,. Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 2005; 280 (12): 11583-11589.